Eli Lilly plans to center its European launch of oral obesity treatment Foundayo on the telehealth channel, according to International chief Patrik Jonsson, as reported by Reuters and cited by FiercePharma. Jonsson noted that the company’s decision to sell Foundayo through government channels will hinge on how pricing is affected by the most‑favored‑nations (MFN) deal Lilly signed with the United States last year.
The move points to a European obesity strategy designed to stay consistent with the company’s U.S. pricing commitments. By choosing telehealth distribution at launch, Lilly may sidestep certain government reference pricing pressures while testing early demand for an oral obesity therapy. Analysts will be watching to see whether the MFN obligations, linking parts of international pricing to U.S. benchmarks, limit what the company can charge in EU markets. It also raises a different signal: that virtual platforms are taking shape as viable entry points for chronic disease treatments. Weight‑management drugs especially, which already draw direct‑to‑consumer interest.
The strategy could ripple across peers navigating similar cross‑market pricing constraints. Should telehealth adoption prove strong, other manufacturers might try hybrid launches combining private‑pay digital access with later government reimbursement deals. For public payers, that may introduce new pressure to establish frameworks for obesity drugs already sold direct‑to‑consumer. Investors, meanwhile, are expected to monitor how the MFN clause interacts with European price referencing, since that dynamic could influence not only Foundayo’s profit profile but also how large pharmas shape future U.S.-EU pricing structures. And then, the market will decide where this model fits.
